Lipocine Earnings Call Transcripts
Fiscal Year 2025
-
LPCN 1154, an oral brexanolone for postpartum depression, is in phase III trials and aims to provide rapid, 48-hour outpatient relief with a strong safety profile. The FDA has agreed a single phase III study will suffice for NDA submission, targeted for mid-2026.
-
Two lead oral therapies are advancing: 2401 for obesity management, with a phase II trial starting Q3 and data expected late Q1 next year, and 1154 for postpartum depression, in phase III with NDA filing projected in about a year. Cash runway extends at least 12 months.
Fiscal Year 2024
-
LPCN2401, an oral androgen receptor agonist, demonstrated improved body composition by reducing fat and increasing lean mass in obese men, with additional benefits when combined with vitamin E. The therapy was well-tolerated, with a favorable safety profile and potential for use alone or with GLP-1 agonists to address lean mass loss.